Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants

Completed 30 enrolled Duke University Lantheus Medical Imaging · collab

RandomizedParallel-groupDouble-blindDiagnostic

Summary

The purpose of this study is to assess the image quality of Ablavar-enhanced MR angiography of the central veins of the chest, and to determine whether dose reduction can be performed while maintaining image quality. This will be a prospective randomized study, in which healthy volunteers will be recruited to undergo a central veins magnetic resonance angiogram (MRA). They will receive either the FDA-approved dose or a lower dose of Ablavar. Quantitative and qualitative analysis will be performed on the images.

Timeline

Start: 2011-08
Primary completion: 2012-07
Completion: 2013-07

Publications

Kim CY, Heye T, Bashir MR, Gebhard TA, Merkle EM. Gadofosveset-enhanced magnetic resonance angiography of the thoracic vasculature in the equilibrium phase: feasibility and impact of dose. J Comput Assist Tomogr. 2013 Sep-Oct;37(5):732-6. doi: 10.1097/RCT.0b013e318299dde9.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Gadofosveset	Diagnostic / imaging agent	0.01 mmol	Intravenous
Subject	Gadofosveset	Diagnostic / imaging agent	0.02 mmol	Intravenous
Subject	Gadofosveset	Diagnostic / imaging agent	0.03 mmol	Intravenous

Indications

No indication recorded.